Tanreqing injection for acute bronchitis disease: A systematic review and meta-analysis of randomized controlled trials

Wang, Pei; Liao, Xing; Xie, Yan-Ming; Chai, Yan; Li, Ling-Hui

doi:10.1016/j.ctim.2016.02.008

Cited by 34 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the most common TRQ-related ADRs related to the skin and appendages, and the majority ADRs occurred within the first 2 h of TRQ administration, being similar to the results reported in previous studies (Shen et al, 2007;Li et al, 2010;Zhong et al, 2010;Xie et al, 2014;Wang et al, 2016;Wang et al, 2019). However, it is important to note that the incidences of TRQ-related AEs and ADRs seen in our study are higher than those seen in TRQ clinical trials (0.3% vs. 0.1~0.14%) (Shen et al, 2007;Li et al, 2010;Zhong et al, 2010;Xie et al, 2014;Wang et al, 2016), highlighting the importance of post-marketing surveillance. Our study included a broad range of patients, including those with a history of allergy, infants, and the elderly who were excluded from the TRQ clinical trials (Shanghai Kaibao Pharmaceutical Co., LTD, unpublished;Shen et al, 2007).…”

Section: Discussionsupporting

confidence: 92%

The Incidence and Risk Factors for Adverse Drug Reactions Related to Tanreqing Injection: A Large Population-Based Study in China

Zhuo

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Tanreqing injection (TRQ) is a traditional Chinese medicine commonly used in China to treat pulmonary diseases presenting as phlegm-heat syndrome. Robust data on the safety of TRQ from real-world observational cohorts are currently lacking. Objective: To evaluate as the incidence, type, and predictors of adverse events (AEs) and adverse drug reactions (ADRs) of TRQ in clinical practice in China. Methods: We conducted a population-based cohort, multicenter study to evaluate the incidence, manifestation, outcomes, and risk factors of AEs and ADRs following TRQ use in China. Between April 2014 and May 2015 a total of 30,322 consecutive inpatients/ emergency attendance patients from 90 hospitals across China administrated TRQ were followed-up for 7 days. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using logistic regression to identify predictors of ADRs. Results: The incidence of AEs and ADRs was 1.4 and 0.3%, respectively. Skin and subcutaneous tissue disorders were the most common ADRs. All ADRs were mild or moderate in severity, except for one serious case of anaphylactic reaction. The majority of ADRs (72.8%) occurred in the first 2 h after TRQ administration. Two-thirds of patients (66.1%) in the study were prescribed TRQ off-label, including infants aged ≤24 months. A history of food allergy (OR 4.50, 95% CI: 1.35-15.00), drug allergy (OR 2.77, 95% CI: 1.56-4.94), and fast infusion speed (off-label use) (OR 2.10, 95% CI: 1.27-3.50) were associated with an increased risk of ADRs. Conclusion: TRQ is well tolerated in the general population, yet off-label use is prevalent. Efforts are required to educate prescribers to adhere to the drug label in order to minimize potential patient harm.

show abstract

Section: Discussionsupporting

confidence: 92%

The Incidence and Risk Factors for Adverse Drug Reactions Related to Tanreqing Injection: A Large Population-Based Study in China

Zhuo

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…TRQ is a type of compound Chinese medicine commonly used in China with clinically proven effectiveness [4][5][6][7][8][9][10]. It is often applied in the treatment of upper and lower respiratory tract infections.…”

Section: Discussionmentioning

confidence: 99%

“…It consists of extracts from Radix Scutellariae baicalensis, bear bile powder, Cornu Caprae Hircus, Flos lonicerae, and Forsythiae Fructus. Because of its ability to clear heat, reduce phlegm, and eliminate toxic effects, this drug is often used to alleviate symptoms such as fever, cough, di culty in expectoration, sore throat, dry mouth, reddish/crimson tongue, and yellow coating on tongue experienced in upper and lower respiratory tract infections and lung diseases [4][5][6][7][8][9][10]. TRQ, as a fast-acting and effective modern medication that comes in ready-to-use formulation, has been used increasingly in clinical situations.…”

Section: Introductionmentioning

confidence: 99%

“…TRQ, as a fast-acting and effective modern medication that comes in ready-to-use formulation, has been used increasingly in clinical situations. Though clinical studies and experiments in the past have con rmed TRQ as a natural broad-spectrum antiviral drug [5,6,11] the molecular mechanism behind its antiviral function has not yet been fully understood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Network Pharmacology-based Analysis of the Molecular Mechanism of Tanreqing in the Treatment of the Coronavirus Disease 2019 (COVID-19)

Yang

Wen

Zheng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This paper discusses the molecular mechanism of Tanreqing (TRQ) in the treatment of the coronavirus disease 2019 (COVID-19) using the network pharmacology approach. Our study provides new ideas on the laboratory research and clinical treatment of the disease. Method: Information on the chemical constituents of TRQ and the genes targeted by the disease was collected. The common gene targets of the drug and the disease were input into the Search Tool for the Retrieval of Interacting Genes/Proteins（STRING）database to understand the interaction among target proteins. The protein–protein interaction (PPI) network and a network of the chemical constituents of TRQ and their targets were constructed using Cytoscape. Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using the R program and other relevant software packages. Results: Twenty-eight active chemical constituents and 365 gene targets were identified for TRQ. Out of these genes, 113 were also found to be involved in the pathogenesis of the disease. Enrichment analysis revealed the therapeutic role that TRQ could have played in the treatment of COVID-19, via the regulation of important pathways such as the renin–angiotension system, neuroactive ligand–receptor interaction, phospholipase D (PLD) signaling pathway, calcium signaling pathway, and the hypoxia-inducible factor 1 (HIF-1) signaling pathway. Conclusions: This study attempts to predict the molecular mechanism of TRQ in the treatment of COVID-19, and suggests TRQ intervention through multiple targets and pathways in processes including inflammatory response, immune regulation, and apoptosis during the treatment of the disease. This study indicates the potential rational application of TRQ in the clinical treatment of COVID-19.

show abstract

“…Mycoplasma pneumoniae infection is also a common cause. Administration of anti-infective agents is the main treatment method for acute bronchitis (4)(5)(6). Long-term treatment with large doses of antibiotics results in an increase of bacterial resistance and dysbacteriosis as well as an enhancement of toxic side effects.…”

Section: Introductionmentioning

confidence: 99%

Changes of Treg and Th17 cells as well as cytokines in children with acute bronchitis

Xue

Chen

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate changes of T-regulatory (Treg) and T-helper (Th)17 cells as well as cytokines in peripheral blood of children with acute bronchitis, and to explore the roles of these cells in the pathogenesis of acute bronchitis. A total of 126 children who had presented at Renji Hospital (Shanghai, China) with acute bronchitis were selected as the observation group and 30 healthy children were selected as the control group. Th17/Tregs in the peripheral blood of the children of the observation group and the control group was detected by flow cytometry. The levels of cytokines interleukin (IL)-17, IL-22, IL-10 and transforming growth factor (TGF)-β in peripheral blood serum were detected by ELISA. Compared with those in the control group, Treg cells, the Treg/Th17 ratio as well as serum IL-10 and TGF-β levels were significantly decreased in the observation group (P<0.05), while Th17 cells as well as serum levels of IL-17 and IL-22 were significantly increased (P<0.05). In conclusion, Treg/Th17 and the expression of associated cytokines lost their balance in children with acute bronchitis, suggesting that Treg and Th17 cells as well as their cytokines may be involved in the pathogenesis of acute bronchitis. It may be of certain guiding significance to detect Treg/Th17 and levels of serum cytokines in peripheral blood for clinical treatment.

show abstract

Tanreqing injection for acute bronchitis disease: A systematic review and meta-analysis of randomized controlled trials

Cited by 34 publications

References 13 publications

The Incidence and Risk Factors for Adverse Drug Reactions Related to Tanreqing Injection: A Large Population-Based Study in China

The Incidence and Risk Factors for Adverse Drug Reactions Related to Tanreqing Injection: A Large Population-Based Study in China

A Network Pharmacology-based Analysis of the Molecular Mechanism of Tanreqing in the Treatment of the Coronavirus Disease 2019 (COVID-19)

Changes of Treg and Th17 cells as well as cytokines in children with acute bronchitis

Contact Info

Product

Resources

About